SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

Muhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, Ralph A. DeFronzo
May 1, 2016; 39:717-725
Cardiovascular Disease and Diabetes
Diabetes Care: Most-Read Full-Text Articles





  • Twitter
  • del.icio.us
  • Digg
  • Facebook
  • Technorati
  • Reddit
  • Yahoo Buzz
  • StumbleUpon

Leave a Reply

Your email address will not be published. Required fields are marked *